Page 271 - medicina-integrativa_compress

CAPÍTULO 25 INFECCIONES CANDIDIÁSICAS RECIDIVANTES 265

Para las cepas de Candida potencialmente • Ácido bórico, 600 mg por vía intravaginal
resistentes, considérese: cada 24 h durante 14 días. B B 2 2

• Terconazol vaginal (Terazol®)
En los casos recidivantes y resistentes:
(supositorios de 80 mg, crema al 0,8%). B B 2 2
Aplíquese a la hora de acostarse durante • Tratamiento de mantenimiento con
3-7 días. fluconazol, 100 a 250 mg una vez a la A A 2 2
semana a largo plazo.
En la candidiasis vulvovaginal complicada:
• En algunos casos recidivantes y resistentes
• Fluconazol oral, 150 mg cada 72 h durante puede necesitarse politerapia con ácido
9-14 días. A A 2 2 B B 2 2
bórico, flucitosina o nistatina por vía
tópica e itraconazol oral.
• Ketoconazol oral, 200 mg cada 24 h o cada
12 h por vía oral durante 14 días. A A 2 2

BIBLIOGRAFÍA 20. Spinillo A, Pizzoli G, Colonna L, et al: Epidemiologic characteristics
of women with idiopathic recurrent vulvovaginal candidiasis. Obstet
1. Foxman B, Barlow R, D’Arcy H, et al: Candida vaginitis: Self-reported Gynecol 81:721-727, 1993.
incidence and associated costs. Sex Transm Dis 27:230-235, 2000. 21. Foxman B: Epidemiology of vulvovaginal candidiasis: Risk factors.
2. Ferrer J: Vaginal candidosis: Epidemiological and etiological factors. Am J Public Health 80:329-331, 1990.
Int J Gynecol Obstet 71:521-527, 2000. 22. Donders GF, Prenen H, Verbeke G, et al: Impaired tolerance for
3. Geiger AM, Foxman B: Risk factors in vulvovaginal candidiasis: glucose in women with recurrent vaginal candidiasis. Am J Obstet
A case-control study among college students. Epidemiology 7: Gynecol 187:989-993, 2002.
182-187, 1996. 23. Spinillo A, Capuzzo E, Acciano S, et al: Effect of antibiotics use on
4. Horowitz B, Edelstein SW, Lippman L: Sexual transmission in the prevalence of symptomatic vulvovaginal candidiasis. Am J
candida. Obstet Gynecol 65:883-886, 1987. Obstet Gynecol 187:989-993, 1999.
5. Nyirjesy P, Sobel JD: Vulvogaginal candidiasis. Obstet Gynecol Clin 24. Nixon SA: Vulvovaginal candidiasis: The role of patient
North Am 30:671-684, 2003. noncompliance in treatment success. Am J Obstet Gynecol
6. Clenney TL, Jorgensen SK, Owen M: Vaginitis. Clin Fam Pract 165:1207-1209, 1991.
7:57-66, 2005. 25. Meyer H, Gottlicher S: Psychosocial factors in vulvovaginal mycosis:
7. Eckert LO, Hawes SE, Stevens CE, et al: Vulvovaginal candidiasis: A multivariate long-term study. Mycoses 41:49-53, 1988.
Clinical manifestations, risk factors, and management algorithm. 26. Irving G, Miller D, Robinson A, et al: Psychological factors
Obstet Gynecol 92:757-765, 1998. associated with recurrent vulvovaginal candidiasis: A preliminary
8. Sobel JD, Faro S, Force RW, et al: Vulvovaginal candidiasis: study. Sex Transm Infect 74:334-338, 1998.
Epidemiologic, diagnostic, and therapeutic considerations. Am J 27. Hilton E, Isenberg HD, Alpenrstein P, et al: Ingestion of yogurt
Obstet Gynecol 178:203-211, 1998. containing Lactobacillus acidophilus as prophylaxis for candida
9. Bergman JJ, Berg AD, Schuseweiis R, et al: Clinical comparison of vaginitis. Ann Intern Med 116:353-357, 1992.
microscopic and culture techniques in the diagnosis of candida 28. Shalev E, Battino S, Weiner E: Ingestion of yogurt containing
vaginitis. J Fam Pract 18:569-552, 1984. Lactobacillus acidophilus compared with pasteurized yogurt as
10. Ledger WJ, Polaneczky MM, Yih MC, et al: Difficulties in the prophylaxis for recurrent candidal vaginitis and bacterial vaginosos.
diagnosis of Candida vaginitis. Infect Dis Clin Pract 9:66-69, 2000. Arch Fam Med 5:593-596, 1996.
11. Rylander E, Berglund, AL, Krassny C, et al: Vulvovaginal Candida in 29. Redondo-Lopez V, Cook RL, Sobel JD: Emerging role of lactobacilli
a young sexually active population: Prevalence, and association with in the control and maintenance of the vaginal bacterial microflora.
oro-genital sex and frequent pain at intercourse. Sex Transm Infect Rev Infect Dis 12:856-872, 1990.
80:54-57, 2004. 30. Reid G, Buce AW, Fraser N, et al: Oral probiotics can resolve
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
12. Reed BD, Gorenflo DW, Gillespie BW, et al: Sexual behaviors and urogenital infections. FEMS Immunol Med Microbiol 30:49-52, 2001.
other risk factors for candida vulvovaginitis. J Women’s Health- 31. Osset J, Garcia E, Bartholem RM, et al: Role of lactobacilli as protection
Based Med 9:645-655, 2000. against vaginal candidiasis. Med Clin (Barc) 117:285-288, 2001.
13. Reed BD, Zazove P, Pierson CL, et al: Candida transmission and 32. Hilton E, Isenberg HD: Lactobaccilles GG: Vaginal suppositories and
sexual behaviors as risks for repeat episodes of Candida vaginitis: J Clin Microbiol 33:1433, 1995.
vulvovaginitis. J Woman’s Health (Larchmt) 12:979-989, 2003. 33. Williams AB, Yu C, Toshima K, et al: Evaluation of two self-care
14. Reed BD, Slattery ML, French TK: The association between dietary treatments for prevention of vaginal candidiasis in women with
intake and reported history of Candida vulvovaginitis. J Fam Pract HIV. J Assoc Nurses AIDS Care 12:51-57, 2001.
29:509-515, 1989. 34. Pirotta M, Chondros P, Grover S, et al: Effect of Lactobacillus in
15. Spinillo A, Capuzzo E, Nicola S, et al: The impact of oral contra - preventing post-antibiotic vulvovaginal candidiasis: A randomized
ception on vulvovaginal candidiasis. Contraception 51:293-297, controlled trial. BMJ 329:465-548, 2004.
1995. 35. Watson MC, Grimshaw JM, Bond CM, et al: Oral versus intra-
16. Barbone F, Austin H, Louv WC, et al: A follow-up study of methods of vaginal imidazole and triazole antifungal agents for the treatment of
contraception, sexual activity, and rates of trichomoniasis, candidiasis, uncomplicated vulvovaginal candidiasis: A systematic review. Br J
and bacterial vaginosis. Am J Obstet Gynecol 85:993-998, 1995. Obstet Gynecol 109:85-95, 2002.
17. Hooten TM, Roberts PL, Stamm WE: Effect of recent sexual activity 36. Sobel JD, Chaim W: Treatment of Torulopsis glabrata vaginitis:
and use of diaphragm on vaginal flora. Clin Infect Dis 19:274-278, Retrospective review of boric acid therapy. Clin Infect Dis 24:649-
1994. 652, 1997.
18. Hellberg D, Zdolsek B, Nilsson S, Mardh PA: Sexual behavior of 37. Richter SS, Galask RP, Messer SA, et al: Antifungal susceptibilities of
women with repeated episodes of vulvovaginal candidiasis. Eur J Candida species causing vulvovaginitis and epidemiology of
Epidemiol 11:575-579, 1995. recurrent cases. J Clin Microbiol 43:2155-2162, 2005.
19. Bradshaw CS, Morton AN, Garland SM, et al: Higher-risk behavioral 38. Sobel JD, Wiesenfeld HC, Marten M, et al: Maintenance of
practices associated with bacterial vaginosis compared with vaginal fluconazole treatment for recurrent vulvovaginal candidiasis. N Engl
candidiasis. Obstet Gynocol 106:105-114, 2005. J Med 351:876-883, 2004.